Feverfew--an antithrombotic drug?
The effects of an extract of the plant feverfew on the interaction of platelets with surfaces coated with human collagens of type III and IV (CIII, CIV), and on the integrity of the endothelial cell (EC) monolayer in perfused rabbit aorta were studied. It was shown that feverfew extract (FE) inhibited the deposition of [51Cr]-labelled platelets on both CIII and CIV in a dose-dependent way. Similar concentrations of FE were needed to inhibit formation of surface-bound aggregates in CIII and platelet spreading on CIV in both platelet-rich plasma and GFP. When aorta segments were perfused in situ with a physiological salt solution, the addition of FE to the solution protected the EC monolayer from spontaneous injury. The results indicate that feverfew may have antithrombotic potential in addition to its claimed benefit in fever, migraine and arthritis.
Loesche
W
W
Institute of Pathological Biochemistry, Medical Academy of Erfurt, GDR.
Mazurov
A V
AV
Voyno-Yasenetskaya
T A
TA
Groenewegen
W A
WA
Heptinstall
S
S
Repin
V S
VS
D000818:Animals; D001011:Aorta; D001792:Blood Platelets / Q000187:drug effects / Q000648:ultrastructure; D003094:Collagen; D004730:Endothelium, Vascular / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D010477:Perfusion; D010936:Plant Extracts / Q000494:pharmacology*; D010946:Plants, Medicinal; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D012717:Sesquiterpenes / Q000494:pharmacology*; D020903:Tanacetum parthenium
D005343:Fibrinolytic Agents; D010936:Plant Extracts; D012717:Sesquiterpenes; D003094:Collagen